IYH is trading at $76.18, up 5.22% before the September 8, 2026 open, amid optimism over AstraZeneca’s FDA accelerated approval of Etcamah.
- Etcamah is an ESR1-directed breast-cancer treatment used with CDK4/6 inhibitors; approval includes a companion diagnostic.
- The move appears unusually large relative to available sector news; U.S. index futures are lower, with no major U.S. economic release scheduled.
- Etcamah-related optimism may support oncology sentiment but does not independently explain the full 5.22% advance.